Development of an optimized refolding process for recombinant Ala-Glu-IGF-1

Protein Eng. 1992 Dec;5(8):797-806. doi: 10.1093/protein/5.8.797.

Abstract

Denatured and reduced N-terminal extended insulin-like growth factor-1 (AE-IGF-1) was purified from Escherichia coli extracts and subjected to in vitro folding. The renaturation process was shown to be a function of the redox potential of the solution. Folding by different methods had no significant effect on the renaturation. A maximal yield of 60% (w/w) was obtained. The folded AE-IGF-1 was enzymatically converted to IGF-1. The major by-product (20% w/w) was identified as scrambled IGF-1. Enzymatic digestion at alkaline and acidic pH suggested two possible disulphide bond arrangements; (i) Cys6-Cys47, Cys18-Cys61, Cys48-Cys52; or (ii) Cys6-Cys52, Cys18-Cys61, Cys47 and Cys48 being in their reduced forms. Energy minimization and molecular modelling suggested that the scrambled IGF-1, having reduced cysteines at positions 47 and 48, was the energetically most stable conformation of the two.

Publication types

  • Comparative Study

MeSH terms

  • Amino Acid Sequence
  • Aminopeptidases / pharmacology
  • Binding, Competitive
  • Circular Dichroism
  • Cysteine
  • Endopeptidases / genetics
  • Humans
  • Insulin-Like Growth Factor I / analogs & derivatives
  • Insulin-Like Growth Factor I / drug effects
  • Insulin-Like Growth Factor I / genetics
  • Insulin-Like Growth Factor I / metabolism*
  • Models, Molecular
  • Molecular Sequence Data
  • Molecular Weight
  • Peptide Mapping
  • Protein Denaturation
  • Protein Engineering
  • Protein Folding*
  • Receptor, IGF Type 1 / metabolism
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism
  • Sequence Homology, Amino Acid

Substances

  • Recombinant Proteins
  • insulin-like growth factor I, N-Ala-Glu-
  • Insulin-Like Growth Factor I
  • Receptor, IGF Type 1
  • Endopeptidases
  • Aminopeptidases
  • Cysteine